



***Two new appointments to BioAlliance Pharma's Supervisory Board
in phase with the company's development***

Paris, October 21, 2009 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.

The Supervisory Board has co-opted André Ulmann MD, PhD (founder and CEO of HRA Pharma since 1996) and the company ING Belgium (represented by Denis Biju-Duval, BEng, MBA, Head of ING Belgium's private equity team since 2001) following the departure of Georges Hibon and Philippe Taranto.

"I wish to thank Georges Hibon and Philippe Taranto for their work, which greatly benefited from their international experience in pharmaceuticals and finance" stated Dominique Costantini, President and CEO, BioAlliance Pharma.

New Board member André Ulmann will contribute his entrepreneurial experience within HRA, a fast-growing European company which develops and commercializes drugs in the reproductive health and endocrinology markets. Furthermore, the core BioAlliance Pharma shareholder ING Belgium has confirmed its midterm commitment to the company.

"I am delighted to welcome these two major players with a reinforced presence of major shareholders in the Supervisory Board", stated Jean-Marie Zacharie, Chairman of the Supervisory Board. *"With their support BioAlliance Pharma will continue to strengthen its growth strategy"*, added Dominique Costantini.

Furthermore, AGF Private Equity (another core shareholder and a current Board member) has appointed Rémi Droller (Partner, managing investments in Healthcare) as its permanent representative. Rémi Droller holds an M.Phil. in Molecular Biology and a Masters in Innovation Management.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com